Breaking News Instant updates and real-time market news.

LB

L Brands

$18.15 /

+0.14 (+0.78%)

07:18
01/09/20
01/09
07:18
01/09/20
07:18

L Brands lowers Q4 EPS view to about $1.85 vs. previous guidance of about $2.00

The company expects to report fourth quarter earnings per share of about $1.85 compared to its previous guidance of about $2.00, against the $1.97 consensus.

  • 27

    Feb

LB L Brands
$18.15 /

+0.14 (+0.78%)

01/03/20 Jefferies
Jefferies says use strength in L Brands on competitor upgrade to sell shares
01/03/20
Fly Intel: Top five analyst upgrades
01/03/20 BofA
L Brands upgraded to Buy from Neutral at BofA
01/03/20 BofA
L Brands upgraded to Buy from Neutral at BofA

TODAY'S FREE FLY STORIES

Conference/Events
Azure Power management to meet with Roth Capital » 04:55
02/17/20
02/17
04:55
02/17/20
04:55
AZRE

Azure Power

$13.70 /

+0.21 (+1.56%)

Meetings to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General news
FX Action: USD-CAD edged out a two-week low » 04:00
02/17/20
02/17
04:00
02/17/20
04:00

FX Action: USD-CAD edged…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
FX Update: The dollar and most other currencies have been stable » 03:40
02/17/20
02/17
03:40
02/17/20
03:40

FX Update: The dollar and…

FX Update: The dollar and most other currencies have been stable in quiet early-week trading so far. This came with the main Chinese equity indices posting 2%-plus gains after China's Finance Minister said on Sunday that Beijing would roll out targeted and phased tax and fee cuts and with the PBoC lowering one of its interest rates and making another liquidity injection. Other stock markets in Asia were mixed. The number of new cases in the coronavirus continued to increased, though the consensus view seems to remain that peak contagion will likely been seen in March. Japan's Nikkei 225 underperformed, closing with a 0.7% loss following weaker than expected Q4 GDP data, which showed a 1.6% q/q contraction versus the median forecast for -0.9%. Q3 data were also revised down, and the data come amid expectations for a dismal current quarter performance given the impact of measures to contain the virus outbreak in China and Japan, and elsewhere. Among the main currencies, EUR-USD has been plying a narrow range just above the 34-month seen on Friday at 1.0827. EUR-JPY and EUR-CHF have been doing likewise about their respective four-month and five-year lows of Friday. USD-JPY has posted a sub-15 pip range just below Friday's 107.91 peak so far. Cable has continued to consolidate gains seen mid last week following signs that the government is gearing up a fiscally expansive policy. The pair has been holding with about 1.3030-50, off from the two-week high of last Thursday at 1.3069. AUD-USD has traded slightly firmer, managing to lift just above its Friday high in making a peak at 0.6733. USD-CAD edged out a two-week low, at 1.3233. A big focus will be on flash manufacturing PMI surveys for February, due at the end of the week out of Eurozone, UK and U.S. Note that U.S. markets will be closed today.

General news
Asian Market Update: » 03:05
02/17/20
02/17
03:05
02/17/20
03:05

Asian Market Update:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Paramount Group management to meet with Morgan Stanley » 16:42
02/16/20
02/16
16:42
02/16/20
16:42
PGRE

Paramount Group

$14.84 /

+0.15 (+1.02%)

Group Dinner Meeting with…

Group Dinner Meeting with President & CEO Behler and CFO Paes will be held in New York on February 25 hosted by Morgan Stanley.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
8x8, Inc. management to meet with Morgan Stanley » 16:38
02/16/20
02/16
16:38
02/16/20
16:38
EGHT

8x8, Inc.

$20.41 /

-0.25 (-1.21%)

Meeting to be held in New…

Meeting to be held in New York on February 20 hosted by Morgan Stanley.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Bausch Health management to meet with Morgan Stanley » 16:36
02/16/20
02/16
16:36
02/16/20
16:36
BHC

Bausch Health

$27.74 /

+0.305 (+1.11%)

Meeting to be held in New…

Meeting to be held in New York on February 19 hosted by Morgan Stanley.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Piper Sandler biotech analyst to hold a KOL luncheon » 16:04
02/16/20
02/16
16:04
02/16/20
16:04

Analysts hold a GU…

Analysts hold a GU Oncology Key Opinion Leader Luncheon Meeting with Dr. Arjun Bala in New York on February 21 hosted by Piper Sandler.

Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call » 16:03
02/16/20
02/16
16:03
02/16/20
16:03

Alternative Energy &…

Alternative Energy & Environmental Services Analyst Windham discusses advanced nuclear energy systems with TerraPower on an Analyst/Industry conference call to be held on February 24 at 11 am.

Conference/Events
Cowen Washington policy strategist to hold an analyst/industry conference call » 16:01
02/16/20
02/16
16:01
02/16/20
16:01

Washington Research…

Washington Research Policy Strategist Krueger holds U.S. Blues: Delegate Download--Morning After (Nevada) Analyst/Industry conference call to be held on February 24 at 10:30 am.

Conference/Events
Stephens oil and gas analysts to hold an analyst/industry conference call » 15:59
02/16/20
02/16
15:59
02/16/20
15:59

Oil & Gas Analysts,…

Oil & Gas Analysts, along with Brandon Barnes, Senior Analyst for Bloomberg Intelligence, discuss the current state of the energy-related infrastructure in North America, with a specific focus on oil & gas pipeline construction on an Analyst/Industry conference call to be held on February 18 at 11 am.

Conference/Events
Cantor Fitzgerald biotech & specialty pharma analysts to hold a luncheon » 15:57
02/16/20
02/16
15:57
02/16/20
15:57
PFE

Pfizer

$36.49 /

-0.43 (-1.16%)

, LLY

Eli Lilly

$141.13 /

-0.75 (-0.53%)

, DERM

Dermira

$18.75 /

+0.01 (+0.05%)

, REGN

Regeneron

$399.34 /

+0.57 (+0.14%)

, INCY

Incyte

$78.42 /

+0.34 (+0.44%)

, ARNA

Arena Pharmaceuticals

$54.01 /

+0.18 (+0.33%)

Specialty Pharma Analyst…

Specialty Pharma Analyst Chen, Biotech Analysts Young & Merle, along with Key Opinion Leaders Dr. Goldberg, Skin Laser & Surgery Specialists of NY & NJ and Dr. Weinberg, Forest Hills Dermatology Group, discuss the competitive landscape in atopic dermatitis at a Group Luncheon Meeting being held at Cantor's New York offices on February 24 at 12 pm.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Cellcom Israel announces negotiations to purchase Golan Telecom » 15:27
02/16/20
02/16
15:27
02/16/20
15:27
CEL

Cellcom Israel

$4.04 /

-0.08 (-1.94%)

Cellcom Israel announced…

Cellcom Israel announced that it is in negotiations with Golan Telecom's, or Golan Telecom, shareholders, in regards to possible purchase of its holdings in Golan Telecom. The company added that it cannot guarantee that such discussions will mature into a transaction.

Hot Stocks
Bristol-Myers announced five-year follow-up results from Phase 3 CheckMate -025 » 15:25
02/16/20
02/16
15:25
02/16/20
15:25
BMY

Bristol-Myers

$66.38 /

+0.31 (+0.47%)

Bristol-Myers Squibb…

Bristol-Myers Squibb announced five-year follow-up results from the Phase 3 CheckMate -025 study, which continue to demonstrate that treatment with Opdivo delivers superior overall survival and objective response rates in patients with previously treated advanced or metastatic renal cell carcinoma compared to those treated with everolimus. With an extended minimum follow-up of 64 months, patients treated with Opdivo continue to demonstrate OS benefit with 26% of patients alive compared to 18% of patients treated with everolimus. Additionally, the percentage of patients experiencing an objective response was 23% for Opdivo versus 4% for everolimus and the median duration of response for Opdivo was also maintained longer than for everolimus. The overall safety profile was consistent with that observed in previously reported analyses from CheckMate -025 in patients with RCC. No new safety signals or drug-related deaths occurred with extended follow-up.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Bristol-Myers announced updated results from Phase 3 CheckMate -214 study » 15:23
02/16/20
02/16
15:23
02/16/20
15:23
BMY

Bristol-Myers

$66.38 /

+0.31 (+0.47%)

Bristol-Myers Squibb…

Bristol-Myers Squibb announced updated results from the Phase 3 CheckMate -214 study evaluating the combination of Opdivo plus Yervoy versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma. With a minimum follow-up of 42 months, the combination of Opdivo plus Yervoy continues to show superior overall survival, objective response rates, duration of response and complete response rates. The safety profile for Opdivo plus Yervoy was consistent with prior findings and no new safety signals or drug-related deaths occurred with extended follow-up. A significant OS benefit was observed in both patients from the intermediate- and poor-risk and the intent-to-treat populations treated with Opdivo plus Yervoy compared to those treated with sunitinib alone. Of the patients treated with Opdivo plus Yervoy who experienced a complete response, per independent review, that response was ongoing in 84% and 86% of patients in the IP and ITT populations, respectively.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Mirati Therapeutics announces trial initial data in Renal Cell Carcinoma » 08:45
02/16/20
02/16
08:45
02/16/20
08:45
BMY

Bristol-Myers

$66.38 /

+0.31 (+0.47%)

, MRTX

Mirati Therapeutics

$92.14 /

-2.25 (-2.38%)

Mirati Therapeutics…

Mirati Therapeutics (MRTX) announced the presentation of initial data from an ongoing investigator sponsored Phase 1/2 clinical trial of sitravatinib in combination with Bristol-Myers' (BMY) nivolumab in patients with advanced clear cell renal cell cancer who have documented progression on a prior VEGF-targeted therapy. As of the data cut-off date of January 1, 2020, 38 out of 40 patients enrolled were evaluable for response at greater than 12 weeks on therapy. 15/38 patients achieved a confirmed partial response including one PR that has improved to an unconfirmed complete response. 35/38 patients achieved clinical benefit. Initial median progression-free survival was 10.3 months. Median overall survival has not yet been reached with 30/38 patients still on study as of the data cut-off date. The combination has been well-tolerated with manageable adverse events.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Opening Day: Revolution Medicines shares soar in trading debut » 08:20
02/16/20
02/16
08:20
02/16/20
08:20
RVMD

Revolution Medicines

$28.00 /

-0.86 (-2.98%)

, GRIL

Muscle Maker

$3.94 /

-0.06 (-1.50%)

, HUIZ

Huize

$10.57 /

+0.06 (+0.57%)

, PASG

Passage Bio

$0.00 /

+ (+0.00%)

Shares of Revolution…

Open Full Text

Conference/Events
Cellectar Biosciences to hold a conference call » 14:35
02/15/20
02/15
14:35
02/15/20
14:35
CLRB

Cellectar Biosciences

$2.90 /

+0.03 (+1.05%)

Key Opinion Leader Dr.…

Key Opinion Leader Dr. Sikander Ailawadhi provides an update of the CLR 131 Phase 1 and Phase 2 Hematology focused trials on a conference call to be held on February 19 at 10:30 am. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Hard-seltzer consumption growth 'excellent news' for Sam Beer, Barron's says » 11:04
02/15/20
02/15
11:04
02/15/20
11:04
STZ

Constellation Brands

$203.85 /

+2.68 (+1.33%)

, TAP

Molson Coors

$55.23 /

-0.11 (-0.20%)

, BUD

AB InBev

$73.51 /

-0.21 (-0.28%)

, SAM

Boston Beer

$408.59 /

-1.79 (-0.44%)

Hard seltzer has grown…

Hard seltzer has grown from near zero a few years ago to 2.6% the size of beer today, which is excellent news for Boston Beer (SAM), Jack Hough writes in this week's edition of Barron's. Typical of the bunch is Truly Hard Seltzer, which is made by Boston Beer, the author notes, adding that AB InBev (BUD), Molson Coors (TAP), and Constellation Brands (STZ) are among those in or joining the mix. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
ICE's busted bid for eBay 'an opening for investors,' Barron's says » 08:46
02/15/20
02/15
08:46
02/15/20
08:46
EBAY

eBay

$38.17 /

+0.99 (+2.66%)

, ICE

IntercontinentalExchange

$96.83 /

+2.62 (+2.78%)

The news that ICE (ICE)…

The news that ICE (ICE) was interested in buying eBay (EBAY) promptly sent the exchange company's stock sharply lower and eBay's sharply higher, but then everything fell apart as no one understood why a financial exchange would want to own an online marketplace, Steven Sears writes in this week's edition of Barron's. ICE's interest in eBay indicates that the exchange business model may soon evolve anew, the author notes, adding that the eBay play is a sign of a possible future. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Lloyds stock a post-Brexit 'pure U.K. banking play,' Barron's says » 08:42
02/15/20
02/15
08:42
02/15/20
08:42
LYG

Lloyds Banking

$2.93 /

-0.085 (-2.82%)

Investors looking to bet…

Investors looking to bet on a Brexit-fueled jump in Britain's economy should consider buying shares in U.K.-based financial powerhouse Lloyds Banking, Simon Constable writes in this week's edition of Barron's. The stock is cheap and highly geared to the U.K. economy, and investors will also get paid a hefty dividend while they wait, the author notes. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Bed Bath's hidden assets might be worth about $1B, Barron's says » 08:40
02/15/20
02/15
08:40
02/15/20
08:40
BBBY

Bed Bath & Beyond

$11.18 /

-0.63 (-5.34%)

Pain and patience are in…

Pain and patience are in store for Bed Bath & Beyond shareholders, Carleton English writes in this week's edition of Barron's. With continuing drops in same-store sales expected as the company corrects its pricing and product mix, Wall Street is hoping Bed Bath & Beyond can pull other levers in the short term to boost its stock price-namely, asset sales, the author notes. Investors Barron's spoke with see a roughly $900M opportunity in aggregate if non-core brands such as PersonalizationMall.com, Cost Plus World Market, and others are sold-with hopes that deals will be announced quickly. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Facebook, Google facing real regulatory risk, Barron's says » 08:16
02/15/20
02/15
08:16
02/15/20
08:16
FB

Facebook

$214.21 /

+1.09 (+0.51%)

, AAPL

Apple

$324.91 /

-0.02 (-0.01%)

, GOOGL

Alphabet Class A

$1,518.35 /

+4.81 (+0.32%)

, GOOG

Alphabet

$1,519.63 /

+5.05 (+0.33%)

For months now,…

For months now, regulators, legislators, activists, and presidential candidates have been calling out the toxic impact that big tech platforms are having on privacy, security, and consumer choice, and there are signs that regulation is starting to hurt, Eric Savitz writes in this week's edition of Barron's. But it is actually the self-imposed checks that could be most damaging to tech's bottom line in the months to come, with Google (GOOGL) beginning to limit cookies in its Chrome browser and Apple (AAPL) adding a feature in its iPhone software that alerts consumers when an app tracks their location, the author notes. Meanwhile, Facebook (FB) is starting to feel the effects of restrictions on both ad targeting and measurement, as the company says that "the majority of that impact lies in front of us." Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Natural gas stocks to be avoided except for Cabot, Cheniere, Barron's says » 08:02
02/15/20
02/15
08:02
02/15/20
08:02
LNG

Cheniere Energy

$54.98 /

+0.17 (+0.31%)

, COG

Cabot Oil & Gas

$14.80 /

-0.27 (-1.79%)

Natural gas fell below $2…

Natural gas fell below $2 per million British thermal units on Jan. 21, a level at which most U.S. producers can't make money drilling new wells and absent a ban on hydraulic fracturing or fracking in the U.S., excess supply will probably depress prices for years, Avi Salzman writes in this week's edition of Barron's. That could make most of the industry's stocks poor investments, with exceptions such as Cabot Oil & Gas (COG) and Cheniere Energy (LNG), the author contends. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Week in Review: How Trump's policies moved stocks » 07:34
02/15/20
02/15
07:34
02/15/20
07:34
AMZN

Amazon.com

$2,135.08 /

-14.65 (-0.68%)

, MSFT

Microsoft

$185.38 /

+1.64 (+0.89%)

, TSLA

Tesla

$799.95 /

-4.05 (-0.50%)

, GM

General Motors

$34.76 /

-0.535 (-1.52%)

, WKHS

Workhorse Group

$3.32 /

-0.235 (-6.61%)

, FCAU

Fiat Chrysler

$13.26 /

-0.175 (-1.30%)

, F

Ford

$8.10 /

-0.155 (-1.88%)

, HMC

Honda

$26.80 /

-0.29 (-1.07%)

, NSANY

Nissan

$0.00 /

+ (+0.00%)

, TM

Toyota

$140.10 /

-0.91 (-0.65%)

, DDAIF

Daimler AG

$0.00 /

+ (+0.00%)

, VWAGY

Volkswagen

$0.00 /

+ (+0.00%)

, CSCO

Cisco

$46.97 /

-0.32 (-0.68%)

, NOK

Nokia

$4.33 /

-0.005 (-0.12%)

, ERIC

Ericsson

$9.09 /

+0.015 (+0.17%)

Catch up on the top…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14
    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.